SCHEMBL687593

SCHEMBL687593

O=C(NCc1ccc(F)cc1)NC(=O)N(C1CCCCC1)C1CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.54
RAB9A P51151 3/20 0.54
POLB P06746 2/20 0.54
ALDH1A1 P00352 2/20 0.48
LMNA P02545 2/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HRH3 Q9Y5N1 2/20 0.45
KCNH2 Q12809 1/20 0.45
EPHX1 P07099 3/20 0.45
HPGD P15428 2/20 0.45
NPC1 O15118 1/20 0.45
MAOB P27338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL688798 0.84 SMN1; SMN2 (0.64) SMN1; SMN2RAB9AALDH1A1HRH3NPC1
SCHEMBL9071835 0.80 NPSR1 (0.48) SMN1; SMN2RAB9AALDH1A1LMNAMAPT
SCHEMBL12384849 0.80 NPSR1 (0.48) SMN1; SMN2RAB9AALDH1A1LMNAMAPT
SCHEMBL688704 0.78 NAMPT (0.57) SMN1; SMN2ALDH1A1MAPT
SCHEMBL688513 0.78 MAPT (0.52) ALDH1A1LMNAMAPTHTTNPSR1
SCHEMBL689048 0.73 HPGD (0.57) SMN1; SMN2RAB9AALDH1A1HPGDNPC1
SCHEMBL19064907 0.73 ALDH1A1 (0.67) SMN1; SMN2RAB9APOLBALDH1A1MAPT
SCHEMBL6468546 0.73 RAB9A (0.68) RAB9APOLBALDH1A1LMNAHTT
SCHEMBL687588 0.72 ALDH1A1 (0.43) POLBALDH1A1MAPTNPSR1EPHX1
SCHEMBL688228 0.72 TSHR (0.36) SMN1; SMN2RAB9APOLBALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904438-B1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS NOVO NORDISK AS (DK) 2012-02-29 EP claimed
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators NOVO NORDISK A/S (DK) 2008-12-25 US claimed
EP-1904438-B1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS NOVO NORDISK AS (DK) 2012-02-29 EP disclosed
US-7999114-B2 Dicycloalkylcarbamoyl ureas as glucokinase activators NOVO NORDISK A/S (DK) 2011-08-16 US disclosed
US-7999114-B2 Dicycloalkylcarbamoyl ureas as glucokinase activators NOVO NORDISK A/S (DK) 2011-08-16 US disclosed
US-7999114-B2 Dicycloalkylcarbamoyl ureas as glucokinase activators NOVO NORDISK A/S (DK) 2011-08-16 US disclosed
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators NOVO NORDISK A/S (DK) 2008-12-25 US disclosed
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators NOVO NORDISK A/S (DK) 2008-12-25 US disclosed
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators NOVO NORDISK A/S (DK) 2008-12-25 US disclosed
WO-2007006761-A1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators GCK, HK1, GCKR SMN1; SMN2 4017/4885RAB9A 2712/4885POLB 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.